“The development of tomorrow’s leaders in tumor immunology and immunotherapy is dependent on bringing the best and brightest trainees into the field,“ says SITC President Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey.
Milwaukee, WI (PRWEB) August 01, 2016
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the SITC-Bristol-Myers Squibb Cancer Immunotherapy Translational Fellowship which provides dedicated funding for young investigators to develop innovative treatment strategies. Applications are being accepted now through August 29, 2016. Interested parties can find out more information and apply online at sitcancer.org.
This fellowship award will provide $200,000 over the course of two years in support for cancer immunotherapy to an individual who has an MD or combined MD/PhD degree and a vested interest in furthering the research and translation of cancer immunotherapy.
“The development of tomorrow’s leaders in tumor immunology and immunotherapy is dependent on bringing the best and brightest trainees into the field,“ says SITC President Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey. “The society is grateful to Bristol-Myers Squibb for their visionary leadership in providing the largest contribution to SITC to support a fellowship program to enhance early career development, fostering interaction between academia and industry, and bringing an outstanding opportunity to those individuals dedicated to translational research in tumor immunotherapy.”
“Every day we are learning more about the potential of immunotherapy across a broad range of cancers. With this contribution, and as part of our commitment to leading the advancement of immunotherapy, we proudly support the researchers and scientists who will help drive forward this rapidly evolving field,” says Julie Hambleton, MD, Vice President, Head, US Medical, Bristol-Myers Squibb.
This year’s award recipient will be recognized among peers and luminaries in the field at the 31st Annual Meeting and Associated Programs. Over 2,500 global thought leaders in cancer immunotherapy will gather at this year’s meeting on November 9-13 in National Harbor, MD to share cutting-edge data, participate in scientific exchange and take part in unmatched education courses and networking opportunities.
The future of cancer immunotherapy is rooted in research and education, primarily by early career scientists. To that end, the SITC Forward Fund was established to stimulate the future of the science, development and application of cancer immunotherapy through financially supporting its education and research. This fellowship opportunity is made possible through the SITC Forward Fund and supported by a contribution from the Bristol-Myers Squibb Company.
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a non-profit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, healthcare professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.
About the SITC Forward Fund
The SITC Forward Fund was established to stimulate the future of the science, development and application of cancer immunotherapy through financially supporting its education and research. sitcancer.org
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
# # #